Company news

Pacira BioSciences, Inc. news in 2025

Pacira BioSciences, Inc.'s news releases, calls and decks from 2025, newest first.

View company

DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.

December 30, 2025

Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care

December 17, 2025

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 2, 2025

Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain

December 1, 2025

Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical

November 25, 2025

DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business

November 9, 2025

Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance

November 5, 2025

Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

November 4, 2025

Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control

November 3, 2025

Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025

October 29, 2025

Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee

October 27, 2025

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®

October 26, 2025

Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®

October 22, 2025

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®

October 20, 2025

Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy

October 19, 2025

Pacira BioSciences Reports Second Quarter 2025 Financial Results

August 4, 2025

Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025

July 23, 2025

Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts

July 21, 2025

Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025

June 17, 2025

Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee

June 10, 2025

Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee

May 14, 2025

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

May 13, 2025

Pacira BioSciences Reports First Quarter 2025 Financial Results

May 7, 2025

Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis

May 5, 2025

Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis

May 1, 2025

Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025

April 28, 2025

Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee

April 27, 2025

Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee

April 21, 2025

Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders

April 16, 2025

Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL

April 6, 2025

Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

April 2, 2025

Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025

Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual

March 13, 2025

Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results

February 26, 2025

Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio

February 26, 2025

Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in March

February 25, 2025

Pacira to Report 2024 Financial Results on Thursday February 27, 2025

February 19, 2025

Pacira Announces Updates to Board of Directors

January 29, 2025

Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments

January 20, 2025

Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization

January 9, 2025

Pacira BioSciences Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block

January 6, 2025

Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 1, 2025

Calls in 2025

Decks in 2025